Nano DiagnosiX is a biotechnology startup company developing a platform technology for remote monitoring of various diseases to enable laboratory-quality testing using handheld devices. These devices will allow quantitative assessment of disease-associated biomarkers by customers in their homes, workplaces, etc. In comparison to conventional diagnostics, remote monitoring is quicker and more efficient, can reach more patients, and reduce healthcare costs. The value of a given diagnostic depends on a number of factors, key among which are cost, portability, and accuracy. Nano DiagnosiX’s device delivers all of these factors, and has novel built-in capabilities to monitor disease progression by communicating test results to the patient’s physician. Existing technologies are expensive, non-versatile, immobile, unstable in a handheld format, and often lack sufficient sensitivity. Although Nano DiagnosiX’s long-term plan is to develop a platform technology applicable to a wide range of diseases, its initial efforts will focus on heart failure monitoring to assist cardiologists in treating at risk patients. Heart failure as a result of cardiovascular disease (CVD) is the leading cause of mortality worldwide, with over 19.9 million attributable deaths in 2015. Sadly, a significant number of these deaths could have been prevented through early diagnosis and intervention, which is exactly what Nano DiagnosiX’s testing and monitoring system is designed to achieve. Given the broad impact of CVD, the customer base for Nano DiagnosiX’s device will be very substantial.
Nano Diagnosix started from a decade old research from the University of Southern California (USC), which laid the groundwork for what we do today. Our incredible team of engineers have worked tirelessly to bring Nano Diagnosix to the forefront of the industry. We will continue to work relentlessly to become the technological standard for decentralized diagnostics. Get in touch to learn more.
Current healthcare trends aim to deliver high quality decentralized services to patients for improved care using patient-provided data. Remote monitoring, home testing, and predictive healthcare are critical components in achieving this. Handheld, patient-operated screening and diagnostic tests offer enormous value in comparison to conventional testing, which is laborious, costly, and requires specialized equipment operated by trained technicians. Handheld device testing is faster, more efficient, and reaches more individuals, including those in locations where access to medical care is restricted, such as rural and low-income areas. Nano DiagnosiX’s remote monitoring cardiac biomarker testing device is highly valuable based solely on its combination of simplicity of use, portability, and extremely high sensitivity measurements – which conventional systems fail to achieve. However, in addition to this, our device distinguishes itself from other systems because of its unique built-in monitoring capabilities allowing patient-acquired test results to be sent electronically to their cardiologist via a smartphone app through the cloud. The end result is a great improvement in the quality of patient care, a significantly reduced need for follow-up visits, and a reduction in healthcare costs.
Combined innovations of Nano DiagnosiX’s testing/remote monitoring system compared to existing technologies. (ELISA: enzyme-linked immunosorbent assay, High Sen ELISA: high sensitivity ELISA, Lateral Flow: Lateral Flow Immunoassay, PCR: polymerase chain reaction)
The Possibilities Are Endless
Nano DiagnosiX is developing an innovative monitoring and prediction device that is able to detect biomarkers, antigens, antibodies, and DNA using a novel electronic technique. The biosensor that forms the basis of this device is generated using a proprietary manufacturing process to create a nanoribbon field-effect transistor chip – termed a FemtoSpot. The FemtoSpot leverages electronic signal amplification to detect the binding of the analytes at extremely low concentrations – only a drop of unprocessed blood is required – yet delivers extremely high accuracy results. Another innovative feature of this device is that it will be a highly affordable, compact, and portable hand-held device that will be used directly by the patient without the need for specialized training. In this way, it will parallel the simplicity and convenience of home blood glucose monitors. In stark contrast, conventional lab ELISA-based systems used for cardiac biomarker quantification are large, non-portable systems operated by trained technicians.
The device that Nano DiagnosiX is developing will offer a unique combination of simple, non-invasive, patient-operated cardiac biomarker testing, coupled with built in monitoring capabilities. This will enable timely intervention and treatment of CVD patients resulting in a significant reduction in debilitation and death, and reduced hospitalization costs.
An image of a manufactured Nano Diagnosix’s FemtoSpot chip containing tens of biosensors used for testing
THE NANO DIAGNOSIX TEAM
Ahmad is an expert in nanomaterials semiconductors and devices. He has a PhD in Electrical Engineering from University of Southern California (USC)
Co-Founder and CTO
Di has more than 10 years of experience in biosensor and diagnostic development. Di has a PhD in Biochemistry from University of California, Santa Barbara (UCSB)
Yazeed is an expert in device processing and semiconductor physics. Yazeed has a PhD in Electrical Engineering from University of California-Los Angeles (UCLA)
Co-Founder and Advisor
Chongwu Zhou is a Professor of Electrical Engineering University of Southern California (USC)
GET IN TOUCH
Mailing Address: 907 Westwood Blvd, STE 264
Los Angeles, Los Angeles County 90024
Lab Address: 2265 E Foothill Blvd, Pasadena, CA 91107